Should I buy or sell Repare Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPTX shares. View RPTX analyst ratings or view top-rated stocks .

What is Repare Therapeutics' stock price target for 2024?

4 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $10.00 to $25.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 440.0% from the stock's current price. View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts .

How have RPTX shares performed in 2024?

Repare Therapeutics' stock was trading at $7.30 on January 1st, 2024. Since then, RPTX shares have decreased by 56.0% and is now trading at $3.21. View the best growth stocks for 2024 here .

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RPTX earnings forecast .

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.11. The firm had revenue of $13.05 million for the quarter, compared to analyst estimates of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative trailing twelve-month return on equity of 39.82%.

What ETF holds Repare Therapeutics' stock?

ARK Genomic Revolution ETF holds 2,612,292 shares of RPTX stock, representing 0.68% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA) , Marvell Technology (MRVL) , Adobe (ADBE) , Albertsons Companies (ACI) , Abbott Laboratories (ABT) , AES (AES) , Autodesk (ADSK) and

When did Repare Therapeutics IPO?

Repare Therapeutics (RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RPTX

Repare Therapeutics (RPTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RPTX Stock Alerts

$3.21

-0.13 (-3.89%)

(As of 04/17/2024 ET)

Compare

Today's Range: $3.16
▼
$3.37
50-Day Range: $3.21
▼
$8.41
52-Week Range: $3.08
▼
$13.85

Volume: 79,291 shs
Average Volume: 145,336 shs
Market Capitalization: $118.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.33

Get Repare Therapeutics alerts:

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 440.0% Upside
$17.33 Price Target
Short Interest: Bearish
2.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$54,037 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.74) to ($3.08) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

581st out of 913 stocks

Pharmaceutical Preparations Industry

251st out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Repare Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Repare Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.39% of the float of Repare Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Repare Therapeutics has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Repare Therapeutics has recently increased by 3.40%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Repare Therapeutics does not currently pay a dividend.
Dividend Growth
Repare Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RPTX.

0.0

News and Social Media Coverage

Search Interest
Only 3 people have searched for RPTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Repare Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,037.00 in company stock.
Percentage Held by Insiders
28.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.74) to ($3.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Repare Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Repare Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Repare Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

RPTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RPTX Stock News Headlines

April 2, 2024 | insidertrades.com

Lloyd Mitchell Segal Sells 2,491 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stock

March 28, 2024 | insidertrades.com

Insider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 2,650 Shares of Stock

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | insidertrades.com

Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells $12,693.50 in Stock

March 29, 2024 | investing.com

Repare therapeutics exec sells shares worth $7,000

March 16, 2024 | finance.yahoo.com

RPTX Apr 2024 7.500 call

March 16, 2024 | finance.yahoo.com

RPTX Jul 2024 7.500 call

March 15, 2024 | businesswire.com

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

March 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

March 1, 2024 | finance.yahoo.com

Repare Therapeutics Full Year 2023 Earnings: Misses Expectations

February 29, 2024 | businesswire.com

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

February 28, 2024 | msn.com

SHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) Investors

February 28, 2024 | benzinga.com

Recap: Repare Therapeutics Q4 Earnings

February 28, 2024 | finance.yahoo.com

Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023

February 28, 2024 | businesswire.com

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 24, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

February 22, 2024 | markets.businessinsider.com

Strong Buy: Repare Therapeutics’ Promising Clinical Outcomes in Cancer Therapy

February 17, 2024 | finance.yahoo.com

We're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Rate

February 17, 2024 | finance.yahoo.com

RPTX Mar 2024 7.500 call

February 16, 2024 | businesswire.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)

February 16, 2024 | businesswire.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)

February 15, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX

February 15, 2024 | finance.yahoo.com

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

February 15, 2024 | businesswire.com

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664

See More Headlines

Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RPTX
CUSIP: N/A
CIK: 1808158
Web: www.reparerx.com
Phone: 857-412-7018
Fax: N/A
Employees: 179
Year Founded: 2016

Price Target and Rating

Average Stock Price Target: $17.33
High Stock Price Target: $25.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +440.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,800,000.00
Net Margins: -183.43%
Pretax Margin: -201.79%
Return on Equity: -39.82%
Return on Assets: -31.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.24
Quick Ratio: 6.24

Sales & Book Value

Annual Sales: $51.13 million
Price / Sales: 2.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.03 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 37,000,000
Free Float: 26,456,000
Market Cap: $118.77 million
Optionable: Optionable
Beta: 0.56

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Lloyd Mitchell Segal (Age 60)
President, CEO & Director
Comp: $913.39k
Dr. Michael Zinda Ph.D. (Age 53)
Executive VP & Chief Scientific Officer
Comp: $641.53k
Dr. Maria Koehler M.D. (Age 67)
Ph.D., Executive VP & Chief Medical Officer
Comp: $682.8k
Dr. Daniel Durocher Ph.D.
Co-Founder
Dr. Frank Sicheri Ph.D.
Co-Founder
Dr. Agnel Sfeir Ph.D.
Co-Founder
Mr. Steve Forte (Age 45)
Executive VP & CFO
Comp: $608.52k
Mr. Daniel Belanger
Executive Vice President of Human Resource
Mr. Cameron Black
Executive Vice President of Discovery
Dr. Kim A. Seth Ph.D.
Executive VP & Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPTX shares.
View RPTX analyst ratings or view top-rated stocks.
What is Repare Therapeutics' stock price target for 2024?: 4 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $10.00 to $25.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 440.0% from the stock's current price.
View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts.
How have RPTX shares performed in 2024?: Repare Therapeutics' stock was trading at $7.30 on January 1st, 2024. Since then, RPTX shares have decreased by 56.0% and is now trading at $3.21.
View the best growth stocks for 2024 here.
When is Repare Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPTX earnings forecast.
How were Repare Therapeutics' earnings last quarter?: Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.11. The firm had revenue of $13.05 million for the quarter, compared to analyst estimates of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative trailing twelve-month return on equity of 39.82%.

What ETF holds Repare Therapeutics' stock?: ARK Genomic Revolution ETF holds 2,612,292 shares of RPTX stock, representing 0.68% of its portfolio.
What other stocks do shareholders of Repare Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and
When did Repare Therapeutics IPO?: Repare Therapeutics (RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.
How do I buy shares of Repare Therapeutics?: Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Repare Therapeutics (RPTX) Stock Price, News & Analysis

Repare Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Repare Therapeutics Stock (NASDAQ:RPTX)

RPTX Stock Price History

RPTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

RPTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™